Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 51407-679

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 51407-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51407-679-03cb (pl).jpg (51407 679 03cb (pl))

51407-679-03cb (pl).jpg (51407 679 03cb (pl))
FDA Label Image

51407-680-03cb (pl).jpg (51407 680 03cb (pl))

51407-680-03cb (pl).jpg (51407 680 03cb (pl))
Not available.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
Figure 2 provides an estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over a 24-hour period following the initial dose of study treatment. This data was obtained from pooled Studies 1, 2, 3, and 4. The Kaplan-Meier plot shows the percentage of patients who took the second dose at different time points post-dose. Patients who did not use additional treatments were censored at 24 hours. The plot includes patients who had a headache response at 2 hours and those who did not respond to the initial dose. Remedication within 2 hours post-dose was not allowed.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
This is a figure titled "Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7". It shows the percentage of patients reporting no headache pain after taking Rizatriptan Benzoate 0D Tablets compared to a placebo. The graph displays percentages from 0% to 100%, with time intervals marked on the x-axis.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.